Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 9, 2011, Pages 2291-2294

  Yan, Peng Wei ^a   Huang, Xin En ^a   Yan, Feng ^a   Xu, Lin ^b   Jiang, Yong ^a  

^a Department of Chemotherapy ^*  (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

Chemotherapy; Genetic polymorphisms; Multi drug resistance; Non small cell lung cancer; Platinum

Indexed keywords

ABCB1 PROTEIN, HUMAN; GLYCOPROTEIN P; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; BLOOD; CODON; DRUG RESISTANCE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CODON; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; SURVIVAL RATE;

EID: 84864080004     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al (2003). P-glycoprotein: from genomics tomechanism. Oncogene, 22, 7468-85.
2. Bernal ML, Sinues B, Fanlo A, et al (2003). Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit, 25, 107-111.
3. Dean M, Rzhetsky A, Allikmets R (2001). The human ATP-binding cassette (ABC) transporter superfamily. Genome Res, 11, 1156-66.
4. Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, 2, 48-58
5. Grilli R, Oxman AD, Julian JA (1993). Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol, 11, 1866-72.
6. Illmer T, Schuler US, Thiede C, et al (2002). MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res, 62, 4955-62
7. Jamroziak K, Balcerczak E, Mlynarski W, et al (2002). Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol, 54, 495-500.
8. Jemal A, Siegel R, Ward E, et al (2009). Cancer stacistics.2009. CA Cancer J Clin, 59, 225-49.
9. Li C, Huang XE, Li Y (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
10. Li Y, Huang XE, Jin GF et al (2011). Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. Asian Pac J Cancer Prev, 12, 739-42.
11. Li YH, Wang YH, Li Y, et al (2006). MDR1 gene polymorphisms and clinical relevance. Acta Genetica Sinica, 33, 93-104
12. Klein I, Sarkadi B, Varadi A (1999). An inventory of the human ABC proteins. Biochim Biophys Acta, 1461, 237-62.
13. Licinio J, Wong M L (2002). Pharmacogenomics: the search for individualized therapies. Wiley, Germany, 179-213.
14. Lustberg MB, Edelman MJ (2007). Opimal duration of chemotherapy in advanced non-small-cell lung cancer. Curr Treat Options Oncol, 8, 38-46.
15. Maione P, Rossi A, Sacco PC, et al (2010). Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin Phamrmacother, 11, 2997-3007.
16. Marino P, Pampallona S, Preatoni A, et al (1994). Chemotherapy vs. supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest, 106, 861-5.
17. Obasaju CK, Raju RN, Stinchcombe T, et al (2009). Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC). J Clin Oncol, 27, s416.
18. Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, et al (2003). Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur J Clin Invest, 33, 261-7.
19. Pan JH, Han JX, Wu JM, et al (2009). MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration, 78, 49-55.
20. Rosell R, Cobo M, Isla D, et al (2005). Applications of genomics in NSCLC. Lung Cancer, 50, 33-40.
21. Sakaeda T, Nakamura T, Okumura K (2003). Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics, 4, 397-410.
22. Schaeffeler E, Eichelbaum M, Brinkmann U, et al (2001). Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet, 358, 383-4
23. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.
24. Sohn JW, Lee SY, Lee SJ, et al (2006). MDR1 Polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol, 36, 137-41
25. Song P, Li S, Meibohm B, et al (2002). Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using Real-Time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS PharmSci, 4, 29-34.
26. Souquet PJ, Chauvin F, Boissel JP, et al (1993). Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet, 342, 19-21.
27. Vinolas N, Provencio M, Requart N, et al (2011). Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer, 71, 191-8.
28. Wang D, Johnson A D, Papp AC, et al (2005). Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics, 15, 693-704.
29. Woodahl EL, Ho RJ (2004). The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprtein expression and function. Curr Drug Metab, 5, 11-19
30. World Health Organization (???). WHO handbook for reporting results of cancer treatment pp8, Geneva.
31. Yao CY, Huang XE, Li C, et al (2009). Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev, 10, 859-64.
32. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.